Cardiac adverse effects of gastrointestinal prokinetics

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 12, 1999, Pages 1585-1591

  Tonini, M ^a   De Ponti, F ^b   Di Nucci, A ^a   Crema, F ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450 3A; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; METOCLOPRAMIDE; MICONAZOLE; POTASSIUM CHANNEL; PROKINETIC AGENT; SEROTONIN 4 RECEPTOR; SULPIRIDE; TERFENADINE; TROLEANDOMYCIN; BENZAMIDE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; GASTROINTESTINAL AGENT;

ACTION POTENTIAL; ANTIARRHYTHMIC ACTIVITY; DOSE RESPONSE; DRUG METABOLISM; ENTEROPATHY; HEART DISEASE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SYNCOPE; CLINICAL TRIAL; DRUG EFFECT; FORECASTING; GASTROINTESTINAL MOTILITY; HEART;

BENZAMIDES; CISAPRIDE; CLINICAL TRIALS; DOPAMINE ANTAGONISTS; FORECASTING; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HEART; HUMANS;

EID: 0033258353     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00655.x     Document Type: Review

References (68)

1. Tonini M. Recent advances in the pharmacology of gastrointestinal prokinetics. Pharmacol Res 1996; 33: 217-26.
2. Briejer MR, Akkermans LMA, Schuurkes JAJ. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 631-51.
3. De Ponti F, Malagelada J-R. Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management. Pharmacol Ther 1998; 80: 49-88.
4. Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG. Presynaptic, ganglionic, and gastrointestinal dopamine receptors in periphery. Pharmacol Rev 1985; 37: 165-216.
5. 4 receptor mediated facilitation of the emptying phase of the peristaltic reflex in the guinea-pig isolated ileum. Br J Pharmacol 1993; 110: 1572-8.
6. Tonini M, Spelta V, De Giorgio R, et al. A re-assessment of the pharmacodynamics of levosulpiride in the guinea pig gastrointestinal tract. Gastroenterology 1999; 116: A1093 (Abstract).
7. Tonini M, Galligan JJ. North RA. Effects of cisapride on cholinergic neurotransmission and propulsive motility in the guinea pig ileum. Gastroenterology 1989; 96: 1257-64.
8. Grider JR, Foxx-Orenstein AE, Jin J-G. 5-hydroxytryptramine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115: 370-80.
9. 4 receptors. Trends Pharmacol Sci 1995; 16: 391-8.
10. 4 receptors. FASEB J 1996; 10: 1398-407.
11. 4-like receptors. Br J Pharmacol 1996; 117: 238-9.
12. Bunce KT, Elswood CJ, Ball MT. Investigation of the 5-hydroxytryptamine receptor mechanism mediating the short-circuit current response in rat colon. Br J Pharmacol 1991; 102: 811-6.
13. 4 receptor in the secretory response of human small intestine to 5-HT. Br J Pharmacol 1993; 110: 927-8.
14. 4 receptor in human atrium: facilitation by chronic β-adrenoceptor blockade. Naunyn-Schmiedeberg's Arch Pharmacol 1994; 349: 331-7.
15. 2-adrenoceptors in human atrium: functional implications. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 353: 592-5.
16. 4) receptor agonist cisapride on aldosterone secretion in healthy volunteers. Endocr Res 1998; 24: 749-52.
17. Lefebvre H, Heron F, Contesse V, Delarue C, Vaudry H, Kuhn JM. Effect of the serotonin4 receptor agonist cisapride on plasma aldosterone levels in cirrhotic patients with secondary hyperaldosteronism. Eur J Clin Pharmacol 1998; 53: 479-80.
18. Tonini M, Messori E, Franceschetti GP, et al. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br J Pharmacol 1994; 113: 1-2.
19. 4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists. Br J Pharmacol 1996; 118: 1965-70.
20. Boyd IW, Rohan AP. Urinary disorders associated with cisapride. Med J Aust 1994; 160: 579-80.
21. Pillans PI, Wood MD. Cisapride increases micturition frequency. J Clin Gastroenterol 1994; 19: 336-46.
22. 4 receptor agonists and bladder disorders. Trends Pharmacol Sci 1996; 17: 314.
23. 4 receptors mediate arrhythmias? Trends Pharmacol Sci 1994; 15: 451-5.
24. Ahmad SR, Wolfe SM. Cisapride and torsades de pointes. Lancet 1995; 345: 508.
25. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Inter Med 1995; 155: 765-8.
26. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335: 290-1.
27. 4 receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997; 29: 670-5.
28. Morgan TK, Sullivan ME. An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. Progr Med Chem 1992; 29: 65-108.
29. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential. J Pharmacol Exp Ther 1997; 282: 220-7.
30. Drici MD, Ebert SN, Wang WX, Rodriguez I, Liu XK, Whitfield BH, Woosley RL. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization and the isolated rabbit heart. J Cardiovasc Pharmacol 1999; 34: 82-8.
31. 4 receptors and dissociation from cardiac effects in vivo. J Pharmacol Exp Ther 1999; 288: 1045-52.
32. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drugrelated lengthening of the QT interval. Circulation 1998; 97: 204-10.
33. Kiehn J, Thomas D, Karle CA, Schöls W, Kühler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn-Schmiedeberg's Arch Pharmacol 1999; 359: 212-9.
34. Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999; 10: 272-82.
35. + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273: H2534-8.
36. Puisieux FL, Adamantidis MM, Dumotier BM, Dupuis BA. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996; 117: 1377-9.
37. Rampe D, Roy M-L, Dennis A, Brown AM. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417: 28-32.
38. Montaz L, Varache N, Harry P, et al. Torsades de pointes during sultopride poisoning. J Toxicol Clin Exp 1992; 12: 481-96.
39. Tracqui A, Mutter-Schmidt C, Kintz P, Berton C, Mangin P. Amisulpride poisoning: a report on two cases. Hum Exp Toxicol 1995; 14: 294-8.
40. Adamantidis MM, Kerram P, Dupuis BA. In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fundam Clin Pharmacol 1994; 8: 391-407.
41. Malkoff MD, Ponzillo JJ. Myles GL, Gomcz CR. Cruz-Flores S. Sinus arrest after administration of intravenous metoclopramide. Ann Pharmacother 1995; 29: 381-3.
42. Roden DM, George AL Jr. Structure and function of cardiac sodium and potassium channels. Am J Physiol 1997; 273: H511-25.
43. Wager E, Tooley PJH, Pearce GL, Wilton LV, Mann RD. A comparison of two cohort studies evaluating the safety of cisapride: Prescription-event monitoring and a large phase IV study. Eur J Clin Pharmacol 1997; 52: 87-94.
44. + channel Kv1.5 by the antibiotic erythromycin. Naunyn Schmiedeberg's Arch Pharmacol 1997; 355: 743-50.
45. Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116-52.
46. Corinaldesi R, Stanghellini V, Tosetti C, et al. The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur J Clin Pharmacol 1993; 44: 429-32.
47. Pettignano R, Chambliss R, Darsey E, Heard M, Clark R. Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support. Crit Care Med 1996; 24: 1268-71.
48. Lewin MB, Bryant RM, Fenrich AL, Grifka RG. Cisapride-induced long QT interval. J Pediatr 1996; 128: 279-81.
49. Autret E, Jonville-Bera AP, Champel V. La toxicité cardiaque du cisapride (Prépulsid) mérite d'ètre prise en compte dans sa prescription, en particulier chez le prématuré. Arch Pédiatr 1997; 4; 507-8.
50. Lupoglazoff JM, Bedu A, Faure C, et al. Allongement de l'espace QT sous cisapride chez le nuveau-né et le nourrisson. Arch Pediatr 1997; 4: 509-14.
51. Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berut CI. Proarrhythmia associated with cisapride in children. Pediatrics 1998; 101: 1053-6.
52. Khongphatthanayothin A, Lane J, Thomas D, Yen L, Chang D, Bubolz B. Effects of cisapride on QT interval in children. J Pediatr 1998; 133: 51-6.
53. Gray VS. Syncopal episodes associated with cisapride and concurrent drugs. Ann Pharmacother 1998; 32: 648-51.
54. Bedford TA, Rowbotham DJ. Cisapride. Drug interactions of clinical significance. Drug Safety 1996; 15: 167-75.
55. Doig JC. Drug-induced cardiac arrhythmias: incidence, prevention and management. Drug Safety 1997; 17: 265-75.
56. van Haarst AD, van 't Klooster GA, van Gerven JM. et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998; 64: 542-6.
57. Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors of human cytochrome P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-11.
58. Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993; 105: 1886-99.
59. Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995; 91: 3010-6.
60. Antzelevitch C, Sun ZQ, Zhang ZQ, Van GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996; 28: 1836-48.
61. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-10.
62. Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999; 33: 22-6.
63. Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Alim Pharmacol Ther 1998; 12: 823-37.
64. Gascon MP, Dayer P. Comparative effects of macrolide antibiotics on liver monoxygenases. Clin Pharmacol Ther 1991; 49: 158.
65. Tinel M, Descatoire V, Larrey D, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989; 250: 746-51.
66. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994; 7: 148-56.
67. Von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995; 13: 105-22.
68. Itoh Z. Motilin and clinical application. Peptides 1997; 18: 593-608.